Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 11/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.53 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.53 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | GLP1R | P43220 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4674044 | 1.00 | NOD1 (0.59) | NOD1PTGS1GSTK1GLO1TLR2 | |
| SCHEMBL4675137 | 0.88 | PTGS1 (0.59) | NOD1PTGS1GSTK1GLO1 | |
| SCHEMBL11874868 | 0.87 | NOD1 (0.64) | NOD1PTGS1GSTK1GLO1TLR2 | |
| SCHEMBL11867544 | 0.87 | NOD1 (0.64) | NOD1PTGS1GSTK1GLO1TLR2 | |
| SCHEMBL17075565 | 0.86 | PTGS1 (0.59) | NOD1PTGS1GSTK1GLO1 | |
| SCHEMBL6926435 | 0.86 | PTGS1 (0.59) | NOD1PTGS1GSTK1GLO1 | |
| SCHEMBL1158162 | 0.86 | PTGS1 (0.59) | NOD1PTGS1GSTK1GLO1 | |
| SCHEMBL17075566 | 0.86 | PTGS1 (0.59) | NOD1PTGS1GSTK1GLO1 | |
| SCHEMBL2091575 | 0.86 | PTGS1 (0.59) | NOD1PTGS1GSTK1GLO1 | |
| SCHEMBL11866992 | 0.86 | PTGS1 (0.59) | NOD1PTGS1GSTK1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392639-B1 | PYRUVATE DERIVATIVES | GALILEO LAB INC (US) | 2008-09-17 | — | — | EP | claimed |
| EP-1392639-A4 | PYRUVATE DERIVATIVES | GALILEO LAB INC (US) | 2006-01-25 | — | — | EP | claimed |
| US-6916850-B2 | Pyruvate derivatives | GALILEO PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | claimed |
| EP-1392639-A1 | PYRUVATE DERIVATIVES | Galileo Laboratories, Inc. (US) | 2004-03-03 | — | — | EP | claimed |
| US-20030013656-A1 | Pyruvate derivatives | ALLOY VENTURES, INC. | 2003-01-16 | — | — | US | claimed |
| US-20030013846-A1 | Pyruvate derivatives | ALLOY VENTURES, INC. | 2003-01-16 | — | — | US | claimed |
| WO-2002090314-A1 | PYRUVATE DERIVATIVES | GALILEO LABORATORIES, INC. (US) | 2002-11-14 | — | — | WO | claimed |
| EP-1392639-B1 | PYRUVATE DERIVATIVES | GALILEO LAB INC (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1392639-A4 | PYRUVATE DERIVATIVES | GALILEO LAB INC (US) | 2006-01-25 | — | — | EP | disclosed |
| US-6916850-B2 | Pyruvate derivatives | GALILEO PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| US-6900218-B2 | Pyruvate derivatives | GALILEO PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1392639-A1 | PYRUVATE DERIVATIVES | Galileo Laboratories, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030013846-A1 | Pyruvate derivatives | ALLOY VENTURES, INC. | 2003-01-16 | — | — | US | disclosed |
| US-20030013656-A1 | Pyruvate derivatives | ALLOY VENTURES, INC. | 2003-01-16 | — | — | US | disclosed |
| US-20030013847-A1 | Cytoprotective agents | MONSANTO TECHNOLOGY LLC | 2003-01-16 | — | — | US | disclosed |
| US-20030013657-A1 | Pyruvate derivatives | MONSANTO TECHNOLOGY, LLC. | 2003-01-16 | — | — | US | disclosed |
| WO-2002090314-A1 | PYRUVATE DERIVATIVES | GALILEO LABORATORIES, INC. (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013847-A1 | Cytoprotective agents | PC, PDK1, PDK2 | NOD1 3148/4885PTGS1 308/4885GSTK1 66/4885 |
| US-20030013657-A1 | Pyruvate derivatives | PC, PDK1, PDK4 | NOD1 3084/4885PTGS1 816/4885GSTK1 280/4885 |
| US-20030013846-A1 | Pyruvate derivatives | PC, PDK1, PDK4 | NOD1 3084/4885PTGS1 816/4885GSTK1 280/4885 |
| US-20030013656-A1 | Pyruvate derivatives | PC, PDK1, PDK4 | NOD1 3084/4885PTGS1 816/4885GSTK1 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.